达拉图穆马
医学
多发性骨髓瘤
临床试验
肿瘤科
重症监护医学
不利影响
微小残留病
内科学
硼替佐米
骨髓
作者
Olga Lytvynova,Jenna Jwayyed,Daniel Pastel,Rohan Prasad,Jack Khouri,Louis O. Williams,Sandra Mazzoni,Shahzad Raza,Faiz Anwer
出处
期刊:Antibodies
[MDPI AG]
日期:2024-09-29
卷期号:13 (4): 80-80
标识
DOI:10.3390/antib13040080
摘要
Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. This analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2023, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, objective response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.
科研通智能强力驱动
Strongly Powered by AbleSci AI